Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results ...
AbbVie stock falls 3.6% despite Q4 earnings beat of $2.71/share and 2026 guidance topping estimates as oncology and aesthetics revenue decline.
With a strong presence in Canada, Australia and New Zealand, Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results